Manish Anand, MD
Nephrology · Cincinnati, OHNPI 1235338260
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (51.7%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. 6 manufacturers reported payments, led by Beigene USA, Inc. at 38.9% of the total. Reporting peaked in 2023 at $3,206 and has fallen 91.0% since, to $289 in 2025.
Across 19 payments — averaging $271.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Beigene USA, Inc.$2K
- Travere Therapeutics, Inc.$2K
- Novartis$1K
- Amgen$346
- Mallinckrodt Hospital Products Inc.$58
- GSK$39
Across 28 payments — averaging $13,545 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$196K
- Beigene, Ltd.$87K
- Beone Medicines USA, Inc.$56K
- Genentech, Inc.$40K
What the payments were for
- Consulting fees$1,50029%
- Travel & lodging$2,66752%
- Food & beverage$92718%
- Education$611%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Beigene USA, Inc. | 6 | $2,004 |
| Travere Therapeutics, Inc. | 3 | $1,567 |
| Novartis | 4 | $1,142 |
| Amgen | 3 | $346 |
| Mallinckrodt Hospital Products Inc. | 1 | $58 |
| GSK | 2 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,155 in reported general payments places this provider in the 80th percentile of 450 nephrology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 11 | $14,995 |
| LokelmaSodium Zirconium Cyclosilicate | 13 | $7,960 |
| Valganciclovir Hcl | 31 | $6,849 |
| Tacrolimus | 38 | $5,209 |
| Cinacalcet Hcl | 83 | $5,100 |
| Mycophenolate Mofetil | 38 | $4,487 |
| Potassium Citrate ErPotassium Citrate | 23 | $2,840 |
| Nifedipine ErNifedipine | 114 | $1,638 |
| Sevelamer Carbonate | 11 | $1,088 |
| Torsemide | 40 | $787 |
| Calcitriol | 24 | $496 |
| Prednisone | 154 | $491 |
| Tamsulosin Hcl | 51 | $459 |
| Metoprolol Succinate | 21 | $363 |
| Carvedilol | 91 | $359 |
Paid to pharmacies, not to this prescriber.
Other nephrology in Cincinnati
- Amit GovilCincinnati$298K
- Prabir Roy ChaudhuryCincinnati$205K
- Charuhas ThakarCincinnati$107K
- Chebel KhalilCincinnati$72K
- Arshdeep TindniCincinnati$41K
- Joseph KremerCincinnati$29K
- Tahir SajjadCincinnati$20K
- Silvi ShahCincinnati$14K
- Prakash GudsoorkarCincinnati$10K
- Ahmad AnjakCincinnati$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.